|
|
|
| Factors Influencing Disease-Free Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Combined with Modified Radical Mastectomy |
| TIAN Bo, GAI Zhongren, Bai Ge, et al |
| Hospital of Northwestern Polytechnical University,Xi'an Shaanxi 710072 |
|
|
|
|
Abstract 【Objective】To explore the factors influencing disease-free survival in breast cancer patients treated with neoadjuvant chemotherapy combined with modified radical mastectomy.【Methods】A total of 150 breast cancer patients treated in our hospital, who underwent modified radical mastectomy combined with neoadjuvant chemotherapy, were followed up for 3 years. The endpoint of follow-up was tumor metastasis, recurrence, or death. Patients with disease-free survival of less than 3 years were classified as the poor prognosis group (n=29), while those with disease-free survival of 3 years or more were classified as the good prognosis group (n=121). General data of the two groups were collected, and univariate and multivariate analyses were used to identify factors influencing disease-free survival. 【Results】 During the 3-year follow-up of 150 patients, 16 deaths were recorded, giving an overall survival rate of 89.33%(134/150). There were 6 cases of recurrence and 7 cases of metastasis, resulting in a disease-free survival rate of 80.67%(121/150). The proportion of patients aged ≤45 years, premenopausal status, tumor size >5 cm, clinical stage T3 or T4, positive vascular tumor embolvs, absence of postoperative radiotherapy, negative estrogen receptor (ER)/progesterone receptor (PR) status, and Ki67 index>30% were significantly higher in the poor prognosis group compared to the good prognosis group (P<0.05). Multivariate logistic regression analysis confirmed that these factors above were risk factors affecting postoperative disease-free survival (P<0.05). 【Conclusion】 Age ≤45 years, premenopausal status, tumor size >5 cm, clinical stage T3 or T4, positive vascular tumor thrombus, absence of postoperative radiotherapy, negative ER/PR status, and Ki67 index >30% are risk factors affecting disease-free survival in breast cancer patients treated with neoadjuvant chemotherapy combined with modified radical mastectomy.
|
|
Received: 17 November 2022
|
|
|
|
|
|
[1] SULAK M, AHISKALIOGLU A, YAYIK A, et al. The effect of ultrasound-guided serratus plane block on the quality of life in patients undergoing modified radical mastectomy and axillary lymph node dissection: a randomized controlled study[J].Anaesthesiol Intensive Ther,2022,54(1):48-55.
[2] XIE X, LI H, WANG C, et al. Effect of modified radical mastectomy combined with neo-adjuvant chemotherapy on postoperative recurrence rate, negative emotion, and life quality of patients with breast cancer[J].Am J Transl Res,2022,14(1):460-467.
[3] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2011版)[J].中国癌症杂志,2011,21(5):367-417.
[4] GROVA M M, STRASSLE P D, NAVAJAS E E, et al. The prognostic value of axillary staging following neoadjuvant chemotherapy in inflammatory breast cancer[J].Ann Surg Oncol,2021,28(4):2182-2190.
[5] BUSBAIT S, ALKHALIFA A M, ALJOHANI S, et al. Occult invasive lobular carcinoma presenting as an axillary skin metastatic lesion underwent neoadjuvant endocrine therapy and surgical resection: a case report and review of literature[J].Breast Cancer (Dove Med Press),2022,14(1):145-152.
[6] 黄州,王淑莲,唐玉,等. 乳腺癌新辅助化疗后改良根治术后放疗开始时间对预后的影响[J].中华放射肿瘤学杂志,2019,28(4):280-285.
[7] 梁国刚,高薇丽,王群先,等. 208例T1~2N1M0期乳腺癌改良根治术患者无病生存情况的危险因素分析[J].中华普外科手术学杂志(电子版),2020,14(6):604-607.
[8] 陈勇,李娟,麻丽珍. 乳腺癌改良根治术术中行胸肌间淋巴结清扫术对患者近远期临床预后的影响[J].海南医学,2017,28(3):399-401.
[9] 李福平,王茂,刘超,等. 保留乳头乳晕复合体的乳腺癌改良根治术预后的相关因素分析[J].中华普外科手术学杂志(电子版),2020,14(6):608-611.
[10] 荣庆林,王淑莲,唐玉,等. 临床T1~3N1M0期乳腺癌新辅助化疗和改良根治术后腋窝淋巴结病理阴性患者术后放疗的价值[J].中华肿瘤杂志,2017,39(6):445-452.
[11] 穆凌光,孟少华,范秀廷,等. 乳腺癌改良根治术患者术后复发转移的多因素分析[J].现代肿瘤医学,2018,26(17):2706-2710.
[12] 张锋,张卓,邹丽娟,等. 早期三阴乳腺癌改良根治术后放疗及预后相关因素分析[J].中华放射医学与防护杂志,2018,38(7):510-516.
[13] 邵水丰,葛明华. 乳腺癌患者化疗相关粒细胞减少和ER/PR阳性与预后的关系分析[J].中国妇幼保健,2021,36(21):4899-4902.
[14] 李明. 三阴性乳腺癌患者癌组织中雄激素受体、Ki67的表达及与预后的关系[J].中国综合临床,2022,38(2):164-169.
[15] 黄风琴,余洁,郭智俊,等. 乳腺癌EGFR、Ki-67、CerbB-2表达的临床价值与预后[J].分子诊断与治疗杂志,2022,14(5):764-768. |
|
|
|
2024, Vol. 41 
